Search Results
Your search for all items matches 147 pages
Showing 1 - 50
Ian Chau, MD, on Gastrointestinal Cancers: Real-World Effectiveness of Nivolumab Plus Chemotherapy
Ian Chau, MD, of The Royal Marsden Hospital, discusses reportedly the first study to evaluate the real-world effectiveness of nivolumab as a first-line treatment of advanced gastric, gastroesophageal junction, or esophageal adenocarcinoma. The combination therapy improved overall survival compared...
Anant Ramaswamy, DM, on Advanced Gastric Cancers: New Findings on Adding Docetaxel to Doublet
Anant Ramaswamy, DM, of Tata Memorial Centre, discusses phase III results of a study that added docetaxel to a doublet regimen of fluorouracil or capecitabine and oxaliplatin, which did not improve overall survival in patients with advanced gastroesophageal junction and gastric cancers. Continuing...
Manish A. Shah, MD, on Esophageal Cancer: Long-Term Outcomes of Pembrolizumab and Chemotherapy
Manish A. Shah, MD, of Weill Cornell Medical College, discusses phase III findings of the KEYNOTE-590 study, which shows that, after 5 years, the use of pembrolizumab plus chemotherapy improved survival with durable efficacy, compared with placebo plus chemotherapy, in patients with untreated...
Ian Chau, MD, on Esophageal Squamous Cell Carcinoma: New Data on Nivolumab, Ipilimumab, and Chemotherapy
Ian Chau, MD, of The Royal Marsden Hospital, discusses an analysis from the CheckMate 648 study on quality-adjusted time without symptoms and toxicity in patients with unresectable advanced esophageal squamous cell carcinoma. Patients treated with nivolumab plus ipilimumab and nivolumab plus...
Ken Kato, MD, PhD, on Advanced Esophageal Cancer: Biomarker Analyses From CheckMate 648
Ken Kato, MD, PhD, of Japan’s National Cancer Center Hospital, discusses the first comprehensive findings on biomarkers from the CheckMate 648 study. These results further corroborate the clinical efficacy of nivolumab plus chemotherapy and nivolumab plus ipilimumab in the first-line treatment of...
Michael K. Gibson, MD, PhD, on Esophageal Cancer: Expert Commentary on Two Key Studies
Michael K. Gibson, MD, PhD, of Vanderbilt University Medical Center, discusses phase III findings on chemotherapy plus camrelizumab in the ESCORT-NEO trial of patients with resectable esophageal squamous cell carcinoma; and phase III SKYSCRAPER-08 results on first-line tiragolumab plus atezolizumab ...
Michael K. Gibson, MD, PhD, on Metastatic Esophageal Squamous Cell Carcinoma: New First-Line Systemic Treatment Options
Michael K. Gibson, MD, PhD, of Vanderbilt-Ingram Cancer Center, discusses the importance of developing additional treatment strategies for patients with advanced or metastatic esophageal squamous cell carcinoma and describes the role of immune checkpoint inhibitors. Dr. Gibson also reviews the...
Kohei Shitara, MD, on Gastric or Gastroesophageal Junction Adenocarcinoma: Recent Data on Zolbetuximab Plus mFOLFOX6
Kohei Shitara, MD, of Japan’s National Cancer Center Hospital East, discusses the SPOTLIGHT study’s phase III findings on zolbetuximab plus mFOLFOX6 as first-line treatment for patients with the biomarker claudin-18.2–positive and HER2-negative locally advanced unresectable or metastatic gastric or ...
Filippo Pietrantonio, MD, on Gastric or Gastroesophageal Junction Adenocarcinoma: Recent Data on Treatment With Tremelimumab and Durvalumab
Filippo Pietrantonio, MD, of Italy’s Istituto Nazionale dei Tumori, discusses phase II results from the INFINITY trial of tremelimumab and durvalumab as neoadjuvant treatment of patients with microsatellite instability–high (MSI) resectable gastric or gastroesophageal junction adenocarcinoma...
Nick Pavlakis, PhD, MBBS, on Gastroesophageal Cancer: New Findings on the Use of Regorafenib
Nick Pavlakis, PhD, MBBS, of Australia’s Royal North Shore Hospital, discusses phase III findings from the INTEGRATE IIa study of regorafenib vs placebo in refractory advanced gastroesophageal cancer. The trial provides a platform for the investigation of combination therapy with an immune...
Gulam A. Manji, MD, PhD, on Gastric and Gastroesophageal Junction Adenocarcinomas: New Data on Pembrolizumab Plus Capecitabine and Oxaliplatin
Gulam A. Manji, MD, PhD, of Columbia University Medical Center, discusses phase II results on perioperative combination chemotherapy and pembrolizumab in patients with resectable gastric cancer. The combination appeared to result in many complete pathologic responses (Abstract CT009).
Zev Wainberg, MD, on Gastroesophageal Junction Adenocarcinoma: Early Results With Anti-CD39 Antibody Plus Chemoimmunotherapy
Zev Wainberg, MD, of the University of California, Los Angeles Medical Center, discusses preliminary data on the safety and efficacy of TTX-030, an anti-CD39 antibody, in combination with budigalimab and FOLFOX for the first-line treatment of locally advanced or metastatic gastric or...
Thierry André, MD, on Esophagogastric Adenocarcinoma: New Findings on Nivolumab and Ipilimumab
Thierry André, MD, of Sorbonne University and Saint-Antoine Hospital, discusses phase II results from the GERCOR NEONIPIGA study, which suggests neoadjuvant therapy with nivolumab and ipilimumab may be associated with a high pathologic complete response rate in patients with localized...
Zev A. Wainberg, MD, on Gastric or Gastroesophageal Junction Adenocarcinoma: Follow-up Data on Pembrolizumab and Chemotherapy
Zev A. Wainberg, MD, of the University of California, Los Angeles, discusses an update, of 25 additional months, on phase III safety and efficacy results from the KEYNOTE-062 trial. This study compared pembrolizumab with or without chemotherapy vs chemotherapy alone for patients with PD-L1–positive ...
Kohei Shitara, MD, on Gastric and Esophageal Cancers: Long-Term Follow-up on Nivolumab Plus Chemotherapy
Kohei Shitara, MD, of Japan’s National Cancer Center Hospital East, discusses a long-term data follow-up from CheckMate 649, which support the continued use of nivolumab plus chemotherapy as first-line treatment in patients with advanced gastric, gastroesophageal junction, and esophageal...
Ian Chau, MD, on Esophageal Squamous Cell Carcinoma: Nivolumab, Ipilimumab, and Chemotherapy for Advanced Disease
Ian Chau, MD, of Royal Marsden NHS Foundation Trust, discusses first results of the CheckMate 648 study, which showed that nivolumab plus chemotherapy and nivolumab plus ipilimumab both demonstrated superior overall survival vs chemotherapy alone in patients with advanced esophageal squamous cell...
Mary F. Mulcahy, MD, and Crystal S. Denlinger, MD, on NCCN Guidelines Updates: Gastric and Esophageal Cancers
Crystal S. Denlinger, MD, of Fox Chase Cancer Center, and Mary F. Mulcahy, MD, of the Robert H. Lurie Comprehensive Cancer Center of Northwestern University, discuss biomarkers for determining treatment; immune checkpoint inhibitors; when to employ such treatments as platinum/fluoropyrimidine and...
Wasat Mansoor, MBChB, PhD, on Esophageal Cancer: Quality of Life With Pembrolizumab and Chemotherapy
Wasat Mansoor, MBChB, PhD, of The Christie NHS Foundation Trust, discusses phase III results from the KEYNOTE-590 trial, which showed no deterioration in health-related quality of life when pembrolizumab was added to chemotherapy in patients with metastatic and unresectable esophageal cancers...
Zev A. Wainberg, MD, on Gastric/Gastroesophageal Junction Adenocarcinoma: Bemarituzumab and FOLFOX
Zev A. Wainberg, MD, of UCLA Medical Center, discusses phase II results from the FIGHT study, which combined bemarituzumab with modified FOLFOX6 in first-line treatment of advanced gastric/gastroesophageal junction adenocarcinoma. This is reportedly the first randomized trial of any FGFR inhibitor, ...
Zev A. Wainberg, MD, on PD-L1–Positive Advanced Gastric Cancer: MSI and Combined Positive Score and Pembrolizumab vs Chemotherapy
Zev A. Wainberg, MD, of the UCLA Medical Center, discusses the first subset analysis of how a combined positive score in gastric and gastroesophageal junction cancers related to the efficacy of pembrolizumab in PD-L1–positive disease (Abstract 427).
Steven H. Lin, MD, PhD, on Esophageal Cancer: Proton Beam vs Intensity-Modulated Radiation Therapy
Steven H. Lin, MD, PhD, of The University of Texas MD Anderson Cancer Center, discusses phase II findings that showed proton beam therapy improved total toxicity burden score with no difference in progression-free survival when compared with intensity-modulated radiation treatment (Abstract LBA2).
Can Lymph Node Response to Neoadjuvant Chemotherapy Predict Prognosis in Esophageal Cancer?
In a study published by Urakawa et al in Annals of Surgery, researchers found that the response of lymph nodes to neoadjuvant chemotherapy is more effective in predicting disease recurrence and patient survival in individuals with esophageal cancer than the response of primary tumors....
FDA Approves Pembrolizumab for Some Patients With PD-L1–Positive Esophageal Cancer
On July 30, the U.S. Food and Drug Administration (FDA) approved the programmed cell death protein 1 inhibitor pembrolizumab (Keytruda) as monotherapy for the treatment of patients with recurrent locally advanced or metastatic squamous cell carcinoma of the esophagus whose tumors express programmed ...
Ramucirumab Plus Pembrolizumab in Previously Treated Advanced Gastroesophageal Cancer, NSCLC, and Urothelial Carcinoma
Results from a phase IB trial expansion stage reported in The Lancet Oncology by Herbst et al showed the combination of ramucirumab plus pembrolizumab had manageable toxicity and antitumor activity in previously treated advanced gastroesophageal cancer, non–small cell lung cancer (NSCLC), and ...
FDA Approves New Trastuzumab Biosimilar
Today, the U.S. Food and Drug Administration (FDA) approved trastuzumab-anns (Kanjinti) for all approved indications of the reference product trastuzumab (Herceptin): for the treatment of HER2-overexpressing breast cancer and HER2-overexpressing metastatic gastric or gastroesophageal...
Josep Tabernero, MD, PhD, on Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: Pembrolizumab With or Without Chemotherapy vs Chemotherapy
Josep Tabernero, MD, PhD, of the Vall d’Hebron Institute of Oncology, discusses phase III findings of the KEYNOTE-062 study showing that, for some patients with advanced gastric or gastroesophageal junction cancer, pembrolizumab may improve survival and may be an effective alternative to...
2019 ASCO: KEYNOTE-062: Pembrolizumab With or Without Chemotherapy vs Chemotherapy in Advanced Gastric or GEJ Adenocarcinoma
The randomized, phase III KEYNOTE-062 trial achieved its primary endpoint, showing that for patients with programmed cell death ligand 1 (PD-L1)-positive, HER2-negative, advanced gastric or gastroesophageal junction (GEJ) cancer, initial therapy with pembrolizumab resulted in noninferior overall...
Trastuzumab Deruxtecan in Advanced HER2-Positive Gastric and Breast Cancers
Two phase I studies reported in The Lancet Oncology indicate activity of the antibody-drug conjugate trastuzumab deruxtecan in advanced HER2-positive gastric cancer and advanced HER2-positive breast cancer previously treated with trastuzumab emtansine (T-DM1). Trastuzumab deruxtecan (DS-8201a) is a ...
2019 ASCO: Reduced Chemotherapy Dosages in Elderly Patients With Advanced Gastroesophageal Cancer
A phase III randomized clinical study evaluating the optimum dose of a combination chemotherapy regimen of oxaliplatin and capecitabine in the treatment of advanced gastroesophageal cancer in frail and elderly patients has found that the patients prescribed the lowest dose tested experienced less...
Perioperative Therapy With FLOT vs ECF/ECX in Locally Advanced Gastric Adenocarcinoma
In the German phase II/III FLOT4 trial reported in The Lancet, Al-Batran et al found that perioperative therapy with the docetaxel-based triplet FLOT (fluorouracil [5-FU]/leucovorin, oxaliplatin, and docetaxel) was associated with improved overall survival vs ECF/ECX (epirubicin and cisplatin plus...
Paclitaxel or Cisplatin Plus Fluorouracil in Chemoradiotherapy for Locally Advanced Esophageal Cancer
In the Chinese phase III ESO-Shanghai 1 trial reported in the Journal of Clinical Oncology, Chen et al found that paclitaxel plus fluorouracil did not significantly prolong overall survival vs standard cisplatin plus fluorouracil in definitive concurrent chemoradiotherapy (dCRT) for locally...
AACR 2019: Small Study of Virotherapy Plus Radiotherapy for Patients With Esophageal Cancer Unable to Receive Standard Treatments
The experimental oncolytic adenovirus telomelysin in combination with radiotherapy was safe and showed early clinical efficacy in vulnerable patients with esophageal cancer, according to results from a phase I clinical trial presented by Fujiwara et al at the American Association for ...
FDA Approves Trastuzumab-qyyp in HER2-Overexpressing Breast and Gastric Cancers
The U.S. Food and Drug Administration (FDA) has approved trastuzumab-qyyp (Trazimera), a biosimilar to trastuzumab (Herceptin), for the treatment of human epidermal growth factor receptor-2 (HER2)-overexpressing breast cancer and HER2-overexpressing metastatic gastric or gastroesophageal...
FDA Approves Trifluridine/Tipiracil for Recurrent, Metastatic Gastric and GEJ Adenocarcinoma
On February 22, the U.S. Food and Drug Administration approved trifluridine/tipiracil tablets (Lonsurf)—a fixed combination of trifluridine, a nucleoside metabolic inhibitor, and tipiracil, a thymidine phosphorylase inhibitor—for adult patients with metastatic gastric or...
Addition of First-Line Ramucirumab to Cisplatin and Fluoropyrimidine in Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
In the phase III RAINFALL trial reported in The Lancet Oncology, Fuchs et al found no apparent benefit of the addition of the VEGFR-2 inhibitor ramucirumab to first-line cisplatin and fluoropyrimidine treatment in metastatic gastric or gastroesophageal junction adenocarcinoma. Study Details The...
Effectiveness of EsophaCap Tool in the Diagnosis of Barrett’s Esophagus
Barrett’s esophagus is the only known precursor of esophageal adenocarcinoma. Although endoscopy and biopsy are standard methods for diagnosing Barrett’s esophagus, their high cost and risk limit their use as a screening modality. Researchers sought to develop a screening method based...
Takashi Kojima, MD, on Esophageal Cancer: Results From the KEYNOTE-181 Trial on Immunotherapy vs Chemotherapy
Takashi Kojima, MD, of the National Cancer Center Hospital East, discusses phase III study findings on pembrolizumab vs chemotherapy as second-line treatment for advanced esophageal cancer (Abstract 2).
Manish A. Shah, MD, on Gastric Cancer: Results From the GAMMA-1 Study on First-Line Combination Therapy
Manish A. Shah, MD, of NewYork–Presbyterian/Weill Cornell Medical Center, discusses phase III data on the efficacy and safety of andecaliximab combined with mFOLFOX6 as first-line treatment in patients with advanced gastric or gastroesophageal junction adenocarcinoma (Abstract 4).
FDA Approves Biosimilar Trastuzumab-dttb
On January 18, the U.S. Food and Drug Administration (FDA) approved trastuzumab-dttb (Ontruzant), a biosimilar referencing trastuzumab, across all eligible indications—namely, adjuvant treatment of HER2-overexpressing breast cancer, metastatic breast cancer, and metastatic gastric cancer or...
2019 GI Cancers Symposium: Addition of Andecaliximab to mFOLFOX6 in Treatment-Naive Advanced Gastric or GEJ Adenocarcinoma
A phase I/Ib study found that the addition of andecaliximab, a monoclonal antibody that inhibits matrix metalloproteinase 9, to modified fluorouracil (5-FU), leucovorin, and oxaliplatin (mFOLFOX6) showed activity in gastric and or gastroesophageal junction (GEJ) carcinoma. Based on these...
Hybrid Minimally Invasive Esophagectomy vs Open Esophagectomy in Esophageal Cancer
In a French phase III trial reported in The New England Journal of Medicine, Mariette et al found that a hybrid minimally invasive surgical procedure was associated with reduced postoperative complications vs transthoracic open esophagectomy in patients with resectable cancer of the middle or lower ...
Pembrolizumab in Pretreated Advanced Esophageal Adenocarcinoma or Squamous Cell Carcinoma
As reported in JAMA Oncology by Shah et al, the phase II KEYNOTE-180 trial has shown that pembrolizumab produces durable responses in some patients with pretreated locally advanced or metastatic esophageal adenocarcinoma or squamous cell carcinoma. Study Details In the trial, 121 patients with...
Genetic Assay May Help Predict Disease Relapse in Patients With Gastroesophageal Cancer
A seven-gene assay could improve care for patients with gastroesophageal cancer by predicting their likelihood of relapse after chemotherapy and surgery. These findings were published by Smyth et al in Annals of Oncology. A team at The Institute of Cancer Research (ICR), London, and The Royal...
FDA Pipeline: What’s New in Biosimilars, Drug Reviews, Designations, and More
The U.S. Food and Drug Administration (FDA) recently issued the following new approvals and designations: Approval for Pegfilgrastim Biosimilar The FDA recently approved a pegfilgrastim biosimilar, pegfilgrastim-cbqv (Udenyca). The biosimilar has been approved to decrease the incidence...
ESMO 2018: Pooled Analysis of Influence of Sex on Chemotherapy Efficacy and Toxicity in Esophagogastric Cancer
In an analysis presented by Davidson et al at the European Society for Medical Oncology (ESMO) 2018 Congress (Abstract 619PD_PR), data were pooled from four UK randomized controlled clinical trials of first-line chemotherapy in esophagogastric cancer, finding significant differences in a...
Pertuzumab and Trastuzumab Plus Chemotherapy in HER2-Positive, Metastatic Gastric or Gastroesophageal Junction Cancer
As reported in The Lancet Oncology by Tabernero et al, the phase III JACOB trial showed no significant overall survival benefit of adding pertuzumab (Perjeta) to trastuzumab (Herceptin) plus chemotherapy in first-line treatment of HER2-positive metastatic gastric or gastroesophageal junction...
Immunotherapy in Advanced Esophagogastric Cancer
As reported in the Journal of Clinical Oncology by Janjigian et al, the phase I/II CheckMate-032 study has shown activity of nivolumab (Opdivo) and nivolumab plus ipilimumab (Yervoy) in advanced esophagogastric cancer. In the esophagogastric cohort of the multicohort study, 160 patients (who...
Neoadjuvant Chemoradiotherapy in Locally Advanced Esophageal Cancer
In a Chinese phase III trial reported in the Journal of Clinical Oncology, Yang et al found that adding neoadjuvant chemoradiotherapy to surgery improved survival in locally advanced squamous cell carcinoma of the esophagus. Study Details In the open-label trial, 451 patients with potentially...
European Commission Approves Trastuzumab Biosimilar
The European Commission (EC) has approved Trazimera, a biosimilar to trastuzumab (Herceptin), for the treatment of human epidermal growth factor (HER2)–overexpressing breast cancer and HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma. This approval...
Second-Line Pembrolizumab vs Paclitaxel in Advanced Gastric or Gastroesophageal Junction Cancer
As reported in The Lancet by Shitara et al, the phase III KEYNOTE-061 trial showed no significant overall survival benefit with pembrolizumab vs paclitaxel in patients with advanced gastric or gastroesophageal junction cancer progressing on platinum-fluoropyrimidine treatment with programmed cell...
